Adagio Medical to Present at the BofA Securities 2025 Health Care Conference

Adagio Medical Holdings (NASDAQ: ADGM), a company specializing in catheter ablation technologies for cardiac arrhythmias treatment, has announced its participation in the upcoming BofA Securities Health Care Conference.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/07/2025 - 08:30 AM EDT

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities Health Care Conference on Tuesday, May 13, 2025, at 9:20 a.m. PT at the Encore Hotel in Las Vegas, NV.

Presentation Information
A live and recorded webcast of the presentation will be available at: https://bofa.veracast.com/webcasts/bofa/healthcare2025/id5FQ7Pq.cfm

About Adagio Medical

Adagio Medical is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS^TM Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. IDE Pivotal Study.